Biogen Idec Inc (BIIB) 325.23 $BIIB
Five Large Caps With Earnings Growth Of 25% Or More
at The Street - Tue Aug 05, 10:46AM CDT
By James Dennin for Kapitall. A survey of the Fortune 500 by the Wall Street Journal says that United States companies [...]
Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
PR Newswire - Tue Aug 05, 7:00AM CDT
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a new collaboration agreement with Biogen Idec (NASDAQ: BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis (MS) under its Regulus microMarkers(TM) division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
BioMed Realty Trust To Webcast Investor Day 2014
PR Newswire - Mon Aug 04, 7:00AM CDT
BioMed Realty Trust, Inc. (NYSE: BMR) will webcast its Investor Day 2014 program to be held on Wednesday, August 6, 2014 at the New York Stock Exchange.
Biotech Gets A Lift On Popular Drug, Strong Pipeline
at Investor's Business Daily - Fri Aug 01, 6:13PM CDT
The success of Biogen Idec's (BIIB) oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder. Its biggest seller is Avonex, an injectable MS treatment. Other Biogen...
Stock Market News for August 01, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 9:10AM CDT
Benchmarks suffered their biggest losses in months on Thursday, following a default by Argentina, and a spike in US labor costs
Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
PR Newswire - Fri Aug 01, 8:20AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
Increased Earnings Estimates Seen for Biogen Idec (BIIB): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:57AM CDT
Biogen Idec could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Biogen Idec (BIIB) Highlighted As Momo Momentum Stock
at The Street - Wed Jul 30, 9:00AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
Marketwire - Wed Jul 30, 4:30AM CDT
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced that it has successfully completed a key preclinical milestone in the collaboration with Biogen Idec. Proteostasis has received a multimillion dollar milestone payment as a result of this achievement.
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.59%
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 1.59% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Five Large Caps With Earnings Growth Of 25% Or More
at The Street - Tue Aug 05, 10:46AM CDT
By James Dennin for Kapitall. A survey of the Fortune 500 by the Wall Street Journal says that United States companies [...]
Regulus Enters Into New Collaboration Agreement with Biogen Idec to Identify microRNA Biomarkers in Multiple Sclerosis
PR Newswire - Tue Aug 05, 7:00AM CDT
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a new collaboration agreement with Biogen Idec (NASDAQ: BIIB) to expand its research focused on identifying microRNAs as biomarkers for multiple sclerosis (MS) under its Regulus microMarkers(TM) division. The new research will focus on profiling a large number of whole blood samples from a cohort of MS patients who have been treated with a Biogen Idec MS therapy to identify potential microRNA signatures. Regulus will receive $2M upfront and is eligible for future payments upon achievement of certain milestones related to the identification of potential microRNA signatures.
Acorda Beats on Q2 Earnings & Revenues, Maintains View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Aug 04, 8:20AM CDT
Acorda (ACOR) recorded an improvement in Ampyra revenues and continues to expect Ampyra sales in the range of $328 million - $335 million.
BioMed Realty Trust To Webcast Investor Day 2014
PR Newswire - Mon Aug 04, 7:00AM CDT
BioMed Realty Trust, Inc. (NYSE: BMR) will webcast its Investor Day 2014 program to be held on Wednesday, August 6, 2014 at the New York Stock Exchange.
Biotech Gets A Lift On Popular Drug, Strong Pipeline
at Investor's Business Daily - Fri Aug 01, 6:13PM CDT
The success of Biogen Idec's (BIIB) oral multiple sclerosis (MS) treatment Tecfidera has been well documented in recent quarters, but the company is far from a one-hit wonder. Its biggest seller is Avonex, an injectable MS treatment. Other Biogen...
Stock Market News for August 01, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Aug 01, 9:10AM CDT
Benchmarks suffered their biggest losses in months on Thursday, following a default by Argentina, and a spike in US labor costs
Favorable Court Ruling, Quarterly Performance Reviews, Acquisition Completion, and Contract Renewals - Research Reports on Mylan, Biogen, Medtronic, UnitedHealth and Covidien
PR Newswire - Fri Aug 01, 8:20AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Medtronic, Inc. (NYSE: MDT), UnitedHealth Group Inc. (NYSE: UNH) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5370-100free.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
Increased Earnings Estimates Seen for Biogen Idec (BIIB): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 7:57AM CDT
Biogen Idec could be an interesting play for investors because of its positive short-term momentum and solid earnings estimate revisions
Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.
Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 30, 11:04AM CDT
Companies like Gilead and Biogen came out with impressive numbers thanks to the continued strong performance of new products.
Biogen Idec (BIIB) Highlighted As Momo Momentum Stock
at The Street - Wed Jul 30, 9:00AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Proteostasis Therapeutics Announces Achievement of Preclinical Milestone in Neurodegenerative Diseases Collaboration With Biogen Idec
Marketwire - Wed Jul 30, 4:30AM CDT
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced that it has successfully completed a key preclinical milestone in the collaboration with Biogen Idec. Proteostasis has received a multimillion dollar milestone payment as a result of this achievement.
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 1.59%
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 1.59% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Jul 29, 3:56PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $335.70 to a high of $344.07. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $339.83 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
